Latest News

SIenna Appoints Swiss Distribution Partner 08-Dec-2016

Sienna Cancer Diagnostics Ltd. and Biosystems Switzerland AG have entered an exclusive distribution .. READ MORE

FDA Registration For Sienna - First IVD Product Listing 15-Nov-2016

Sienna Cancer Diagnostics has listed an in-vitro diagnostic (IVD) medical device with the United Sta.. READ MORE

Sienna Receives ISO13485 Certification 14-Oct-2016

Sienna have received formal certification that their Quality Management System complies with the.. READ MORE

Investor Information

Sienna is a public unlisted company headquartered in Melbourne, Australia. In January 2015, Sienna transitioned from a purely Research and Development company to a true commercial entity with product revenues. The company has approximately 150 shareholders and is governed by an experienced board and management team, Sienna has benefited from over $5.7M in R&D Tax Incentive refunds and government grant programs, significantly bolstering investor contributions and facilitating the progress and growth to date. READ MORE


Sienna’s core activities have historically focused on the clinical translation of biomarkers using novel diagnostic technologies for applications in pathology laboratories. The development of inexpensive, high performing in-vitro diagnostic tests is expected to lead to radical changes in the approach to care and assessment of cancer patients – a change welcomed by clinicians and governments. READ MORE

About Sienna

Sienna is a biotechnology company focussed on the development and commercialisation of novel IVD (in vitro diagnostic) tests. Sienna manufactures individual component products for research institutions and pathology laboratories to use in research or in their own laboratory developed tests. Sienna registered their first product with the FDA in 2014, the Anti-hTERT antibody (SCD-A7). READ MORE

Sienna is finalising preparations for registration and launch of the first ever IVD for detection of telomerase as an adjunct to urine cytology for the diagnosis of bladder cancer.

– COO, Matthew Hoskin

Sign up to our newsletter

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059